1. Advancing Care in Genitourinary Cancer: Perspectives From Chicago

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Chapter 1: New Data on Treatment of Advanced or Metastatic RCC

5. RCC Background

6. The Evolving Treatment Landscape of RCC

7. Outcomes by Nephrectomy Status in METEOR

8. Outcomes by Age in METEOR

9. Phase 1/2 Study of Epacadostat + Pembrolizumab in Advanced RCC: ECHO-202/KEYNOTE-037

10. Phase 2 Study of Atezolizumab + Bevacizumab: IMmotion150

12. Immotion150: Conclusions

13. Phase 1b Study of Avelumab + Axitinib in First-Line Advanced RCC: JAVELIN Renal 100

14. Phase 2 Study of Alternate Sunitinib Dosing Schedule in Patients With mRCC

15. Chapter 2: New Data in Adjuvant RCC Treatment

16. Background Localized RCC

17. Phase 3 Trials of Adjuvant VEGFR TKIs in RCC

18. Prognostic Validation of Multigene Recurrence Score in S-TRAC

19. Phase 3 Trial of Adjuvant Pazopanib After Nephrectomy in Locally Advanced RCC: PROTECT

20. PROTECT Trial: Pazopanib Exposure-Response Assessment

21. Phase 3 Trial of Perioperative Nivolumab in Patients With Localized RCC: PROSPER RCC

22. Phase 3 Trial of Atezolizumab as Adjuvant Therapy in High-Risk RCC: IMmotion010

23. Concluding Remarks: Adjuvant RCC Therapy

24. Chapter 3: New Data In First-Line Treatment of Bladder Cancer

25. Immunotherapies Approved in Locally Advanced or Metastatic UC Since 2016

26. Phase 2 Single-Arm Study of Atezolizumab in Patients With mUC Ineligible for Cisplatin: IMvigor210

27. Phase 2 Single-Arm Study of Pembrolizumab in Patients With mUC Ineligible for Cisplatin: KEYNOTE-052

29. Responses to Pembrolizumab by PD-L1 Expression in KEYNOTE-052

30. Safety Profile of Pembrolizumab in UC in KEYNOTE-052

31. KEYNOTE-052: Conclusions

32. Phase 3 Trials of Checkpoint Inhibitor Doublets vs Chemotherapy in First-Line mUC

33. Phase 3 Trials of Chemotherapy Plus Checkpoint Inhibitors in First-Line mUC

34. Pembrolizumab for Treatment of MSI-H or dMMR Tumors

35. Prevalence of MSI in UC and Association With Checkpoint Inhibitor Responses

36. Chapter 4: New Data in Second-Line Treatment of Advanced Bladder Cancer

37. Phase 3 Study of Pembrolizumab in mUC KEYNOTE-045

40. KEYNOTE-045 Other Efficacy Outcomes

42. KEYNOTE-045 Summary

43. Phase 1/2 Study of Durvalumab in mUC

44. Phase 1/2 Study of Epacadostat + Pembrolizumab in Advanced UC: ECHO-202/KEYNOTE-037

45. Concluding Remarks

46. Abbreviations

47. Abbreviations (cont)

48. Abbreviations (cont)

49. Abbreviations (cont)

50. Abbreviations (cont)